Illumina, Inc. announced on 21 September it will buy back cancer screening start-up GRAIL Inc. in a cash and stock deal valued at $8bn, buying out well-known investors such as Amazon’s Jeff Bezos.
Illumina Will Pay $8Bn To Buy Back Cancer Screening Start-Up Grail
Illumina announced today it will buy back Grail to allow faster adoption of its liquid biopsy test.
More from In Vitro Diagnostics
• By
Now that a federal judge has ruled the US FDA exceeded its authority by unilaterally assuming regulatory oversight of lab-developed tests, what’s the agency’s next move? And does it really have one?
• By
The Cologuard Plus test has a sensitivity of 95% and a specificity of 94% for the detection of colorectal cancer; “unmatched accuracy,” according to Exact Sciences.
• By
A federal judge in Texas delivered what is most likely a fatal blow to the US FDA’s final rule, which would have regulated lab-developed tests as medical devices.